Dihexa

A synthetic hexapeptide analog of angiotensin IV, developed at Washington State University. Extraordinarily potent cognitive enhancer and neuroprotective agent, reported to be 10 million times more potent than BDNF at promoting synaptic connectivity.

• Binds hepatocyte growth factor (HGF) receptor c-Met to augment signaling
• Potently stimulates dendritic spine formation and synaptogenesis
• Activates the HGF/c-Met/PI3K pathway for neuronal survival
• Resistant to enzymatic degradation by peptidases
• Crosses the blood-brain barrier via oral administration

• Active cancer (HGF/c-Met pathway involved in tumor growth)
• Pregnancy or breastfeeding
• Uncontrolled hypertension
• History of psychiatric disorders (may exacerbate anxiety)

Store at 2–8°C (36–46°F) for up to 3 months, protected from light and moisture. Oral solution should be prepared fresh or refrigerated and used within 1 week.

Developed by Dr. Joseph Harding and colleagues at Washington State University. Published preclinical data demonstrates remarkable cognitive enhancement in scopolamine-impaired and aged rats. No human clinical trials completed. Patent filed for neurodegenerative disease applications. Safety profile in humans remains uncharacterized.